Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: A single center study in Korea

Hana Park, Ki Hong Choi, Sae-Byeol Choi, Jong Won Choi, Do Young Kim, Sang Hoon Ahn, Kyung Sik Kim, Jin Sub Choi, Kwang Hyub Han, Chae Yoon Chon, Jun Yong Park

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.

Original languageEnglish
Pages (from-to)753-760
Number of pages8
JournalYonsei Medical Journal
Volume52
Issue number5
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Cholangiocarcinoma
Korea
Survival
Hepatocellular Carcinoma
Liver
Recurrence
Neoplasms
Neoplasm Staging
Liver Neoplasms
Portal Vein
Thrombosis
Survival Rate
Neoplasm Metastasis

Keywords

  • Cholangiocarcinoma
  • Combined hepatocellular and cholangiocarcinoma
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma : A single center study in Korea. / Park, Hana; Choi, Ki Hong; Choi, Sae-Byeol; Choi, Jong Won; Kim, Do Young; Ahn, Sang Hoon; Kim, Kyung Sik; Choi, Jin Sub; Han, Kwang Hyub; Chon, Chae Yoon; Park, Jun Yong.

In: Yonsei Medical Journal, Vol. 52, No. 5, 01.09.2011, p. 753-760.

Research output: Contribution to journalReview article

Park, H, Choi, KH, Choi, S-B, Choi, JW, Kim, DY, Ahn, SH, Kim, KS, Choi, JS, Han, KH, Chon, CY & Park, JY 2011, 'Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: A single center study in Korea', Yonsei Medical Journal, vol. 52, no. 5, pp. 753-760. https://doi.org/10.3349/ymj.2011.52.5.753
Park, Hana ; Choi, Ki Hong ; Choi, Sae-Byeol ; Choi, Jong Won ; Kim, Do Young ; Ahn, Sang Hoon ; Kim, Kyung Sik ; Choi, Jin Sub ; Han, Kwang Hyub ; Chon, Chae Yoon ; Park, Jun Yong. / Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma : A single center study in Korea. In: Yonsei Medical Journal. 2011 ; Vol. 52, No. 5. pp. 753-760.
@article{5cb5efa0db22449f9dcaf594e54276d9,
title = "Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: A single center study in Korea",
abstract = "Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0{\%}), 9 (20.9{\%}), 25 (58.1{\%}), and 3 (7.0{\%}) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4{\%}) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1{\%}. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.",
keywords = "Cholangiocarcinoma, Combined hepatocellular and cholangiocarcinoma, Hepatocellular carcinoma",
author = "Hana Park and Choi, {Ki Hong} and Sae-Byeol Choi and Choi, {Jong Won} and Kim, {Do Young} and Ahn, {Sang Hoon} and Kim, {Kyung Sik} and Choi, {Jin Sub} and Han, {Kwang Hyub} and Chon, {Chae Yoon} and Park, {Jun Yong}",
year = "2011",
month = "9",
day = "1",
doi = "10.3349/ymj.2011.52.5.753",
language = "English",
volume = "52",
pages = "753--760",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "5",

}

TY - JOUR

T1 - Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma

T2 - A single center study in Korea

AU - Park, Hana

AU - Choi, Ki Hong

AU - Choi, Sae-Byeol

AU - Choi, Jong Won

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Kim, Kyung Sik

AU - Choi, Jin Sub

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

AU - Park, Jun Yong

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.

AB - Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.

KW - Cholangiocarcinoma

KW - Combined hepatocellular and cholangiocarcinoma

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79960989617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960989617&partnerID=8YFLogxK

U2 - 10.3349/ymj.2011.52.5.753

DO - 10.3349/ymj.2011.52.5.753

M3 - Review article

C2 - 21786439

AN - SCOPUS:79960989617

VL - 52

SP - 753

EP - 760

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 5

ER -